Workflow
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
IncyteIncyte(US:INCY) Businesswireยท2025-09-17 05:00

Group 1 - Incyte announced new 24-week Phase 3 data from the STOP-HS clinical trial program for Povorcitinib in Hidradenitis Suppurativa at EADV 2025 [1]